ATE532073T1 - Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels - Google Patents

Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels

Info

Publication number
ATE532073T1
ATE532073T1 AT04765681T AT04765681T ATE532073T1 AT E532073 T1 ATE532073 T1 AT E532073T1 AT 04765681 T AT04765681 T AT 04765681T AT 04765681 T AT04765681 T AT 04765681T AT E532073 T1 ATE532073 T1 AT E532073T1
Authority
AT
Austria
Prior art keywords
risk
subject
determining
galectin
thrombospondin
Prior art date
Application number
AT04765681T
Other languages
German (de)
English (en)
Inventor
Yigal Pinto
Original Assignee
Univ Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maastricht filed Critical Univ Maastricht
Application granted granted Critical
Publication of ATE532073T1 publication Critical patent/ATE532073T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
AT04765681T 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels ATE532073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
ATE532073T1 true ATE532073T1 (de) 2011-11-15

Family

ID=34306912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765681T ATE532073T1 (de) 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels

Country Status (14)

Country Link
US (5) US7888137B2 (https=)
EP (4) EP1522857A1 (https=)
JP (5) JP4840744B2 (https=)
CN (2) CN102998458B (https=)
AT (1) ATE532073T1 (https=)
AU (2) AU2004284496C1 (https=)
CA (2) CA2542033C (https=)
CY (2) CY1112359T1 (https=)
DK (2) DK2317324T3 (https=)
ES (2) ES2530567T3 (https=)
PL (2) PL1682907T3 (https=)
PT (2) PT1682907E (https=)
SI (2) SI2317324T1 (https=)
WO (1) WO2005040817A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US20100055723A1 (en) * 2007-01-23 2010-03-04 University Of Virginia Patent Foundation Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
BR112012008063A2 (pt) * 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
EP2588111A1 (en) 2010-07-02 2013-05-08 BG Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
JP5787895B2 (ja) * 2010-10-18 2015-09-30 原　英彰 筋萎縮性側索硬化症マーカー及びその利用
EP2460890A1 (en) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
US20120220671A1 (en) * 2011-01-31 2012-08-30 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
ES2750126T3 (es) 2011-03-17 2020-03-25 Critical Care Diagnostics Inc Procedimientos de predicción del riesgo de un resultado clínico adverso
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CA2858601C (en) * 2011-12-08 2020-11-17 Isaac Eliaz Reduction of galectin-3 levels by plasmapheresis
US20150253314A1 (en) * 2012-09-27 2015-09-10 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
WO2014078655A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
CA2973653A1 (en) 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
JP6612864B2 (ja) * 2015-05-28 2019-11-27 京セラ株式会社 切削工具
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用
CA3238590A1 (en) * 2021-11-09 2023-05-19 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
CA2293718A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
ATE476662T1 (de) * 1997-09-05 2010-08-15 Southern Medical Diagnostics P Diagnoseverfahren
DE69830668T3 (de) * 1997-10-24 2011-07-14 Shionogi & Co., Ltd. Verfahren zur inhibierung des abbaus von natriuretischen peptiden und verbesserte methode zum bestimmen der natriuretischen peptide
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
JP3987284B2 (ja) * 1999-01-29 2007-10-03 ロシュ ダイアグノスティックス ゲーエムベーハー Ｎ末端ｐｒｏＢＮＰの同定方法
AU3704500A (en) * 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
JP2003507076A (ja) * 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
WO2001057252A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
JP2004532602A (ja) 2000-04-05 2004-10-28 インサイト・ゲノミックス・インコーポレイテッド 泡沫細胞分化において発現される遺伝子
KR100395254B1 (ko) 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US20030166017A1 (en) * 2000-11-09 2003-09-04 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DE60144493D1 (de) * 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
US7041449B2 (en) * 2001-03-19 2006-05-09 Wisconsin Alumni Research Foundation Methods of screening for compounds that inhibit expression of biomarker sequences differentially expressed with age in mice
US20060019235A1 (en) * 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
CA2483105C (en) * 2002-05-13 2011-05-10 Arexis Ab Autoimmune conditions and nadph oxidase defects
EP1579383A4 (en) 2002-10-24 2006-12-13 Univ Duke BINARY PREDICTION TREE MODELING WITH MANY PREDICTORS AND USES THEREOF FOR CLINICAL AND GENETIC APPLICATIONS
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
US20060257946A1 (en) * 2003-06-06 2006-11-16 Ciphergen Biosystems, Inc Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
WO2006102497A2 (en) * 2005-03-22 2006-09-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) * 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
BR112012008063A2 (pt) * 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.

Also Published As

Publication number Publication date
PL2317324T3 (pl) 2015-10-30
SI1682907T1 (sl) 2012-03-30
JP2010279378A (ja) 2010-12-16
EP1682907A1 (en) 2006-07-26
WO2005040817A1 (en) 2005-05-06
EP1522857A1 (en) 2005-04-13
CA2542033C (en) 2014-04-29
CN1879022B (zh) 2012-10-17
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
CY1112359T1 (el) 2015-12-09
US7888137B2 (en) 2011-02-15
DK2317324T3 (en) 2015-02-16
HK1184534A1 (zh) 2014-01-24
CY1116147T1 (el) 2017-02-08
EP1682907B1 (en) 2011-11-02
US20080193954A1 (en) 2008-08-14
EP2317324B1 (en) 2014-11-12
US8084276B2 (en) 2011-12-27
JP4840744B2 (ja) 2011-12-21
US20110104722A1 (en) 2011-05-05
ES2377012T3 (es) 2012-03-21
AU2009227844A1 (en) 2009-11-26
JP2011177184A (ja) 2011-09-15
JP2014115297A (ja) 2014-06-26
JP5580774B2 (ja) 2014-08-27
JP2007508527A (ja) 2007-04-05
PT1682907E (pt) 2012-02-03
PT2317324E (pt) 2015-02-17
DK1682907T3 (da) 2012-08-13
ES2530567T3 (es) 2015-03-03
JP5789009B2 (ja) 2015-10-07
HK1101426A1 (en) 2007-10-18
CN1879022A (zh) 2006-12-13
JP2015171365A (ja) 2015-10-01
AU2004284496A1 (en) 2005-05-06
AU2004284496C1 (en) 2010-03-04
PL1682907T3 (pl) 2012-03-30
CN102998458B (zh) 2015-07-22
SI2317324T1 (sl) 2015-11-30
EP2919012A1 (en) 2015-09-16
US20130189716A1 (en) 2013-07-25
CN102998458A (zh) 2013-03-27
US20120220532A1 (en) 2012-08-30
US20150037353A1 (en) 2015-02-05
AU2009227844B2 (en) 2012-07-19
EP2317324A1 (en) 2011-05-04
CA2542033A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
ATE532073T1 (de) Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
DE60026337D1 (de) Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
EP2520935A3 (en) Organ-specific proteins and methods of their use
ATE458201T1 (de) Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6
ATE430812T1 (de) Materialien und verfahren zum einfangen von krankheitserregern und zur abtrennung von aurintricarbonsäure aus einer probe
DE60033380D1 (de) Verfahren zur quantifizierung der zahl von leukozyten in einer blutprobe
DE60217351D1 (de) Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens
JP2007508527A5 (https=)
DE602005019475D1 (de) Verfahren zur Bestimmung einer anfänglichen Nukleinsäurekonzentration anhand von real-time Amplifikationsdaten
DE60335276D1 (de) Verfahren zur umrechnung von venösen blutwerten in arterielle blutwerte, system zur verwendung der methode
DE112006002354A5 (de) Analyseverfahren zur Bestimmung eines Organfunktionsparameters unter bevorzugter Verwendung einer wässrigen C-Methacetin-Lösung
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
DE60020347D1 (de) Verfahren zur herstellung einer matrize von chemischen oder biologischen molekülsequenzen für eine chemische oder biologische analysevorrichtung
EP1669761A3 (de) Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials
ATE323282T1 (de) VERFAHREN ZUR BESTIMMUNG EINES ERHÖHTEN RISIKOS EINER FRAU, EIN FOETUS MIT DEM ßDOWN-SYNDROMß ZU TRAGEN
ATE423310T1 (de) Verfahren und mittel zur bestimmung von gesamtsäure
EP1605260A3 (de) Verfahren und Testkit zur Bestimmung des organisch gebundenen Kohlenstoffs (TOC)
ATE465411T1 (de) Verfahren zur bestimmung von anfälligkeit einer person zur infektion
ATE470154T1 (de) Verfahren zur bewertung von insulinresistenz
DE50312755D1 (de) Verfahren zur Bestimmung des Verschleisses eines elektrochemischen Energiespeichers
DE602006013201D1 (de) Verfahren zur bewertung der nierenfunktion einer k
RU2003134132A (ru) Способ экспресс-определения кальция в моче
ATE483983T1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
ATE509277T1 (de) Verfahren zur bestimmung von 1,5-anhydroglucitol unter verwendung von vollblut